Gross Dominique, Reuss Suzanne, Dillier Claudia M, Gerber Andreas C, Weiss Markus
Department of Anaesthesia, University Children's Hospital, Zurich, Switzerland.
Paediatr Anaesth. 2006 Apr;16(4):444-50. doi: 10.1111/j.1460-9592.2005.01780.x.
Tropisetron is a long-acting 5HT3 receptor antagonist and was shown to be effective in the prevention of postoperative nausea and vomiting (PONV) after tonsillectomy. The aim of the study was to compare the effects of early vs late intraoperative administration of tropisetron with regard to prevention of PONV during the first 48 h after extubation.
In a randomized double-blind study, we investigated 120 children aged 1-12 years undergoing general anesthesia for tonsillectomy or adenotonsillectomy. Patients received 0.1 mg x kg(-1) tropisetron (maximum 2 mg) immediately after inhalational induction (early) and establishment of intravenous access or after the end of surgery before extubation (late). PONV and the need for antiemetic rescue medications were recorded within the following 48 h. Patient data were analyzed using t-test, chi-squared test (significance level of alpha = 0.05) and Spearman rank correlation test.
The overall incidence of vomiting was 55.3%, with 60% (36/60) in the early treatment and 51.6% (31/60) in the late treatment group (P = 0.46). The observed time course 48 h postoperatively showed no difference regarding the number of vomiting episodes between the two groups and the need for antiemetic rescue medication. The incidence of nausea was higher in the late application group in the first 6 h after extubation (P = 0.001) and higher in the early application group between 24 and 48 h after extubation (P = 0.02). Morphine and the age over 3 years had a strong influence on the incidence of vomiting.
The intraoperative time point (early vs late) of intravenous administration of a single prophylactic dose of tropisetron has no impact on the incidence of PONV during the first 48 h after tonsillectomy and/or adenoidectomy in children.
托烷司琼是一种长效5HT3受体拮抗剂,已被证明在预防扁桃体切除术后的术后恶心和呕吐(PONV)方面有效。本研究的目的是比较托烷司琼术中早期与晚期给药对拔管后48小时内预防PONV的效果。
在一项随机双盲研究中,我们调查了120名年龄在1至12岁接受扁桃体切除术或腺样体扁桃体切除术全身麻醉的儿童。患者在吸入诱导后立即(早期)并建立静脉通路后或手术结束拔管前(晚期)接受0.1mg·kg⁻¹托烷司琼(最大2mg)。在接下来的48小时内记录PONV情况及使用止吐救援药物的需求。使用t检验、卡方检验(显著性水平α = 0.05)和Spearman等级相关检验分析患者数据。
呕吐的总体发生率为55.3%,早期治疗组为60%(36/60),晚期治疗组为51.6%(31/60)(P = 0.46)。术后48小时的观察时间进程显示,两组之间呕吐发作次数和使用止吐救援药物的需求没有差异。晚期应用组在拔管后的前6小时恶心发生率较高(P = 0.001),早期应用组在拔管后24至48小时恶心发生率较高(P = 0.02)。吗啡和3岁以上年龄对呕吐发生率有很大影响。
单次预防性剂量的托烷司琼静脉给药的术中时间点(早期与晚期)对儿童扁桃体切除术和/或腺样体切除术后48小时内PONV的发生率没有影响。